Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice?

doi:10.1016/j.ijtb.2025.09.005

Back to search

Article

Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice?

The Indian journal of tuberculosis - 1 Apr 2026

Sharma Amit, Chatterjee Poulomi, Shastry Shashank

Abstract excerpt

MDR TB treatment is now facing the perils of emerging resistance to BDQ(bedaquiline) and DLM(delaminid). Both DLM and PRT(pretomanid) belong to the nitroimidazole group of drugs. Drug resistance in Mycobacterium Tuberculosis (MTB) is an ever changing, continuous and evolving process whereby the b...

Topics

Nitroimidazoles
Humans
Antitubercular Agents
Tuberculosis, Multidrug-Resistant
Mycobacterium tuberculosis
Mutation
Drug Resistance, Multiple, Bacterial
Oxazoles

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.